GW Pharma Considered a Reputable Cannabis Company to Invest in

With a major expansion in companies entering the cannabis market, it is difficult to identify reputable companies to invest in.

Earlier this year, the SEC issued warnings of marijuana-related penny stocks proliferating after cannabis legalization became a reality in Colorado, Washington, Oregon and the District of Columbia. The SEC defines penny stocks as “a very small company that trades at less than $5 per share.”

While investing in cannabis companies in the US remains highly speculative, investing in reputable companies, such as GW Pharmaceuticals may produce significant returns.

GW recently released Q4 2014 results, which led to a ten percent spike in share price, mainly because of non-GAAP earnings of $0.20 per share beat mean consensus estimates of -$0.69. GW’s cannabinoid-based drug Sativex is approved for the treatment of spasticity due to multiple sclerosis (MS) in 27 countries outside of the US. The drug is also in Phase III clinical...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.